Nadzeya Haroshka/iStock via Getty Images The US FDA expanded the use of Eli Lilly’s (LLY) Olumiant (baricitinib) for severe alopecia areata to include children 12 years and older. Approval was based on 36-week data from the adolescent cohort of the phase 3 BRAVE-AA-PEDS study that Source link Like this:Like Loading… Related Post navigation Blackstone’s head of private equity to depart – report (BX:NYSE)
